AKTS vs EVO
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
AKTS exhibits weak financial health per the Piotroski F-Score of 3/9, indicating significant operational and profitability concerns, with negative margins, ROE, and ROA. The absence of an Altman Z-Score raises distress risk concerns, particularly given the company's negative earnings and extreme operating losses. Despite a strong analyst consensus of 'strong_buy' and a high target price, the stock trades at an inflated Price/Sales of 188.43 and lacks any intrinsic value anchor. The recent earnings surprises are volatile and predominantly negative, with a 101.51% average miss over the last four quarters, undermining credibility. The 15.2% decline across all time horizons further reflects persistent market skepticism.
EVO shows bearish fundamentals based on deterministic rules. Financial strength is strong (F-Score 6/9). Concerns include weak profitability or high valuation.
Compare Another Pair
Related Comparisons
AKTS vs EVO: Head-to-Head Comparison
This page compares Aktis Oncology, Inc. (AKTS) and Evotec SE (EVO) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.